English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduISPOR announced the publication of a report from the ISPOR Biosimilars Special Interest Group highlighting the need for clearer guidance on when and how to conduct health technology assessments (HTAs) for biosimilars.
Tag: biosimilar
First Report Card on Biosimilars in Oncology
SUMMARY Researchers have developed the first report card on biosimilars for three blockbuster cancer drugs marketed by Genentech/Roche: Rituxan, Avastin and Herceptin. In a Policy Review in The Lancet Oncology, Y. Tony Yang, a professor at the George Washington University…